E-LIB Suche - Ergebnisse für: Angevin, Eric

1

A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-..:

Pruis, Melinda A ; Krebs, Matthew G ; Plummer, Ruth...
The Oncologist. 28 (2023) 12 - p. e1248-e1258 , 2023

Link: https://doi.org/10.1093/..

2

The search for therapeutic targets in lung cancer: Preclini..:

Lefebvre, Anne-Marie ; Adam, Julien ; Nicolazzi, Céline...
Lung Cancer. 184 (2023) - p. 107356 , 2023

Link: https://doi.org/10.1016/..

3

First-in-human study of an OX40 (ivuxolimab) and 4-1BB (uto..:

Hamid, Omid ; Chiappori, Alberto A ; Thompson, John A...
Journal for ImmunoTherapy of Cancer. 10 (2022) 10 - p. e005471 , 2022

Link: https://doi.org/10.1136/..

4

A Phase 1b Study of Telisotuzumab Vedotin in Combination Wi..:

Camidge, D. Ross ; Barlesi, Fabrice ; Goldman, Jonathan W....
JTO Clinical and Research Reports. 3 (2022) 1 - p. 100262 , 2022

Link: https://doi.org/10.1016/..

5

Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedot..:

Camidge, D. Ross ; Morgensztern, Daniel ; Heist, Rebecca S....
Clinical Cancer Research. 27 (2021) 21 - p. 5781-5792 , 2021

Link: https://doi.org/10.1158/..

6

Serum soluble CD26/DPP4 titer variation is a potential prog..:

Kaneko, Yutaro ; Hatano, Ryo ; Hirota, Naoto...
Biomarker Research. 9 (2021) 1 - p. , 2021

Link: https://doi.org/10.1186/..

7

Feasibility and first reports of the MATCH-R repeated biops..:

Recondo, Gonzalo ; Mahjoubi, Linda ; Maillard, Aline...
npj Precision Oncology. 4 (2020) 1 - p. , 2020

Link: https://doi.org/10.1038/..

8

Chemotherapy beyond immune checkpoint inhibitors in patient..:

Martin-Romano, Patricia ; Ammari, Samy ; El-Dakdoukti, Yolla...
European Journal of Cancer. 137 (2020) - p. 117-126 , 2020

Link: https://doi.org/10.1016/..

9

Efficacy of histology-agnostic and molecularly-driven HER2 ..:

Cabel, Luc ; Fuerea, Alina ; Lacroix, Ludovic...
Oncotarget. 9 (2018) 11 - p. 9741-9750 , 2018

Link: https://doi.org/10.18632..

10

Human epidermal receptor family inhibitors in patients with..:

Verlingue, Loic ; Hollebecque, Antoine ; Lacroix, Ludovic...
European Journal of Cancer. 92 (2018) - p. 1-10 , 2018

Link: https://doi.org/10.1016/..

11

Organisational factors influencing early clinical trials en..:

Besle, Sylvain ; Schultz, Emilien ; Hollebecque, Antoine...
European Journal of Cancer. 98 (2018) - p. 17-22 , 2018

Link: https://doi.org/10.1016/..

12

P1.06-044 Costs of Adverse Events (AE) Associated with Canc..:

Chouaid, Christos ; Loirat, Delphine ; Godard, Chloé...
Journal of Thoracic Oncology. 12 (2017) 1 - p. S693 , 2017

Link: https://doi.org/10.1016/..

13

Phase I trial of bortezomib daily dose: safety, pharmacokin..:

Bahleda, Rastislav ; Le Deley, Marie-Cécile ; Bernard, Apexa...
Investigational New Drugs. 36 (2017) 4 - p. 619-628 , 2017

Link: https://doi.org/10.1007/..

14

First-in-human phase 1 of YS110, a monoclonal antibody dire..:

Angevin, Eric ; Isambert, Nicolas ; Trillet-Lenoir, Véronique...
British Journal of Cancer. 116 (2017) 9 - p. 1126-1134 , 2017

Link: https://doi.org/10.1038/..

15

MA09.09 First-In-Human Phase 1 Study of ABBV-399, an Antibo..:

Angevin, Eric ; Strickler, John ; Weekes, Colin...
Journal of Thoracic Oncology. 12 (2017) 1 - p. S395-S396 , 2017

Link: https://doi.org/10.1016/..